or Try an Advanced Search...

    Liver Disease Stocks List

    Symbol Grade Name % Change
    BLTE B Belite Bio, Inc. -0.10
    MIRM B Mirum Pharmaceuticals, Inc. -0.48
    ALGS B Aligos Therapeutics, Inc. 8.74
    GILD C Gilead Sciences, Inc. 1.27
    GALT C Galectin Therapeutics Inc. -3.37
    HEPA C Hepion Pharmaceuticals, Inc. -0.62
    TARA D ArTara Therapeutics, Inc. -0.87
    ALNY D Alnylam Pharmaceuticals, Inc. -0.80
    GRI D GRI Bio, Inc. 7.82
    GYRE D Gyre Therapeutics, Inc. -8.99
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
    Related Stock Lists: Clinical Medicine Drug Development Hepatitis Medicine Non Alcoholic Fatty Liver Disease Steatohepatitis Acid Alcohol Antiviral Therapies Bile Acid Cholestasis Chronic Hepatitis Coronavirus Diabetes Digestive Diseases Hepatitis B Hepatology Intrahepatic Cholestasis Liver Oral Therapy

    Related ETFs - A few ETFs which own one or more of the above listed Liver Disease stocks.

    Symbol Grade Name Weight
    HRTS F Tema Cardiovascular and Metabolic ETF 2.6
    BBP C BioShares Biotechnology Products Fund 2.41
    SBIO C ALPS Medical Breakthroughs ETF 1.47
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 1.43
    ILDR A First Trust Innovation Leaders ETF 0.67
    View all Liver Disease ETFs...
    Compare ETFs
    Compare BBP to ILDR Compare HRTS to ILDR Compare HRTS to SBIO

        Liver Disease Stocks Recent News

        Date Stock Title
        Nov 21 GRI GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
        Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
        Nov 20 BLTE Belite Bio: Interesting Science, But Quite A Few Worries
        Nov 19 ALGS Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
        Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
        Nov 18 GILD Gilead’s Livdelzi shows promise in PBC clinical trial
        Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
        Nov 18 GALT Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
        Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
        Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
        Nov 15 TARA Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
        Nov 15 GILD Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
        Nov 15 GILD Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
        Nov 15 MIRM Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
        Nov 15 GRI GRI Bio reports 9M results
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
        Related Stock Lists: Clinical Medicine Drug Development Hepatitis Medicine Non Alcoholic Fatty Liver Disease Steatohepatitis Acid Alcohol Antiviral Therapies Bile Acid Cholestasis Chronic Hepatitis Coronavirus Diabetes Digestive Diseases Hepatitis B Hepatology Intrahepatic Cholestasis Liver Oral Therapy
        Liver Disease

        Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the course of the problem lasts long, chronic liver disease ensues.

        More about Liver Disease
        Browse All Tags